What is Fasenra?

Fasenra (benralizumab) is a biologic therapy used to treat severe eosinophilic asthma in those that have not responded adequately to asthma medications including high doses of combination medicines such as Advair, Dulera, Symbicort, Breo, or Trelegy.  Fasenra is a medication administered in our office.  The first 3 injections occur every 4 weeks and then every 8 weeks thereafter.  

 

What is Fasenra indicated for?

Fasenra is indicated for individuals 12 years of age and older with severe eosinophilic asthma that has not responded to other asthma medications.

 

How does Fasenra work?

Eosinophils are a type of white blood cell in the body. Individuals with eosinophilic asthma have increased levels of eosinophils in blood and tissues, which worsens inflammation in their lungs and can cause severe asthma attacks. Fasenra binds to the eosinophils and rapidly reduces reduce eosinophil levels in the blood.  This reduction helps prevent asthma attacks, improves breathing and lung function, and better controls asthma symptoms. Fasenra may reduce or completely eliminate a patient’s need to take oral steroids daily. 

 

Want more information about Fasenra?

• Visit the Fasenra manufacturer's website

 

Want information about Fasenra Patient Assistance Program?

• Fasenra Savings Program